Adenosine metabolism in human whole blood. Effects of nucleoside transport inhibitors and phosphate concentration. 1988

D D Dawicki, and K C Agarwal, and R E Parks
Section of Biochemical Pharmacology, Brown University, Providence, RI 02912.

Adenosine (Ado, 10 microM) was metabolized in whole blood within 1 min, primarily to hypoxanthine and ATP. The concentration of Ado, the activities of adenosine deaminase (ADA) and Ado kinase, the Km values for Ado with ADA and Ado kinase, and the substrate inhibition of Ado kinase are factors that govern the Ado metabolism between deamination and phosphorylation. If ADA activity was blocked by 2'-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine. A high phosphate concentration (25 mM) caused marked increases in the formation of IMP. The nucleoside transport inhibitors dilazep (1 microM), dipyridamole (10 microM) and nitrobenzylthioinosine (NBMPR, 1 microM) strongly blocked cellular Ado metabolism. In the presence of nucleoside transport inhibitors, Ado which slowly enters the cell was metabolized principally by Ado kinase rather than ADA. Dilazep, NBMPR and dipyridamole were more effective in blocking Ado uptake and metabolism by erythrocytes suspended in a protein-free medium than by cells suspended in plasma.

UI MeSH Term Description Entries
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D004109 Dilazep Coronary vasodilator with some antiarrhythmic activity. Asta C 4898,Biopropazepan Trimethoxybenzoate,Cormelian,C 4898, Asta,Trimethoxybenzoate, Biopropazepan
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D000248 Adenosine Kinase An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20. Kinase, Adenosine
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D013868 Thioinosine Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503) 6-Mercaptopurine Riboside,NSC-4911,Ribosyl-6-mercaptopurine,6 Mercaptopurine Riboside,Riboside, 6-Mercaptopurine,Ribosyl 6 mercaptopurine

Related Publications

D D Dawicki, and K C Agarwal, and R E Parks
September 1986, Journal of cellular physiology,
D D Dawicki, and K C Agarwal, and R E Parks
January 1998, Advances in experimental medicine and biology,
D D Dawicki, and K C Agarwal, and R E Parks
March 1998, Molecular and cellular biochemistry,
D D Dawicki, and K C Agarwal, and R E Parks
April 1987, Biochemical pharmacology,
D D Dawicki, and K C Agarwal, and R E Parks
August 1976, Biochimica et biophysica acta,
D D Dawicki, and K C Agarwal, and R E Parks
June 1981, Life sciences,
D D Dawicki, and K C Agarwal, and R E Parks
May 1984, The Journal of pharmacology and experimental therapeutics,
D D Dawicki, and K C Agarwal, and R E Parks
July 1991, Journal of molecular and cellular cardiology,
D D Dawicki, and K C Agarwal, and R E Parks
October 1989, The Journal of pharmacology and experimental therapeutics,
D D Dawicki, and K C Agarwal, and R E Parks
August 1967, The Journal of physiology,
Copied contents to your clipboard!